Raymond James Maintains Strong Buy on Apellis Pharmaceuticals, Raises Price Target to $92
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Steven Seedhouse has maintained a 'Strong Buy' rating on Apellis Pharmaceuticals (NASDAQ:APLS) and raised the price target from $89 to $92.
October 06, 2023 | 8:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apellis Pharmaceuticals' stock rating has been maintained as 'Strong Buy' by Raymond James, with a raised price target from $89 to $92.
The 'Strong Buy' rating maintained by Raymond James indicates a positive outlook for Apellis Pharmaceuticals. The raised price target from $89 to $92 suggests that the analyst expects the stock to perform well in the short term. This could potentially lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100